Literature DB >> 33267665

Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Gowthami M Arepally1, Anand Padmanabhan2.   

Abstract

Heparin-induced thrombocytopenia is an immune-mediated disorder caused by antibodies that recognize complexes of platelet factor 4 and heparin. Thrombosis is a central and unpredictable feature of this syndrome. Despite optimal management, disease morbidity and mortality from thrombosis remain high. The hypercoagulable state in heparin-induced thrombocytopenia is biologically distinct from other thrombophilic disorders in that clinical complications are directly attributable to circulating ultra-large immune complexes. In some individuals, ultra-large immune complexes elicit unchecked cellular procoagulant responses that culminate in thrombosis. To date, the clinical and biologic risk factors associated with thrombotic risk in heparin-induced thrombocytopenia remain elusive. This review will summarize our current understanding of thrombosis in heparin-induced thrombocytopenia with attention to its clinical features, cellular mechanisms, and its management.

Entities:  

Keywords:  antibodies; heparin; platelets; thrombocytopenia; thrombosis

Mesh:

Substances:

Year:  2020        PMID: 33267665      PMCID: PMC7769912          DOI: 10.1161/ATVBAHA.120.315445

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  138 in total

1.  Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets.

Authors:  B H Chong; I Fawaz; C N Chesterman; M C Berndt
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

2.  A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.

Authors:  Anand Padmanabhan; Curtis G Jones; Brian R Curtis; Daniel W Bougie; Mia J Sullivan; Namrata Peswani; Janice G McFarland; Daniel Eastwood; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2016-02-19       Impact factor: 9.410

3.  The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.

Authors:  T K Liem; R Teel; S Shukla; D Silver
Journal:  J Vasc Surg       Date:  1997-01       Impact factor: 4.268

Review 4.  Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature.

Authors:  Elizabeth A Jaben; A Sergio Torloni; Rajiv K Pruthi; Jeffrey L Winters
Journal:  J Clin Apher       Date:  2011-04-19       Impact factor: 2.821

5.  Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.

Authors:  W P Jeske; J M Walenga; E Szatkowski; M Ero; J M Herbert; S Haas; M Bakhos
Journal:  Thromb Res       Date:  1997-11-01       Impact factor: 3.944

Review 6.  Thrombosis: tangled up in NETs.

Authors:  Kimberly Martinod; Denisa D Wagner
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

7.  Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG.

Authors:  A Greinacher; U Liebenhoff; V Kiefel; P Presek; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1994-05       Impact factor: 5.249

8.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

Review 9.  Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis.

Authors:  M Arman; K Krauel
Journal:  J Thromb Haemost       Date:  2015-04-21       Impact factor: 5.824

Review 10.  Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Authors:  Brigitte Tardy; Thomas Lecompte; François Mullier; Caroline Vayne; Claire Pouplard
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

View more
  13 in total

Review 1.  Procoagulant platelets: novel players in thromboinflammation.

Authors:  Frederik Denorme; Robert A Campbell
Journal:  Am J Physiol Cell Physiol       Date:  2022-08-22       Impact factor: 5.282

2.  Delayed-onset heparin-induced thrombocytopenia complicated with saddle embolus.

Authors:  Faezeh Sadat Naji; Mahan Shafie; Mahbod Issaiy; Narjes Zarei Jalalabadi; Samaneh Parsa
Journal:  Clin Case Rep       Date:  2022-07-19

Review 3.  Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.

Authors:  Po-Wei Chen; Zong-Yun Tsai; Ting-Hsing Chao; Yi-Heng Li; Charles Jia-Yin Hou; Ping-Yen Liu
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

4.  Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin.

Authors:  B Singh; A Kanack; A Bayas; G George; M Y Abou-Ismail; M Kohlhagen; M Christ; M Naumann; K Moser; K Smock; A Grazioli; D Murray; A Padmanabhan
Journal:  medRxiv       Date:  2021-09-24

5.  Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.

Authors:  Andreas Greinacher; Kathleen Selleng; Raghavendra Palankar; Jan Wesche; Stefan Handtke; Martina Wolff; Konstanze Aurich; Michael Lalk; Karen Methling; Uwe Völker; Christian Hentschker; Stephan Michalik; Leif Steil; Alexander Reder; Linda Schönborn; Martin Beer; Kati Franzke; Andreas Büttner; Boris Fehse; Evi X Stavrou; Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Maike Frye; Thomas Thiele; Stefan Kochanek; Lea Krutzke; Florian Siegerist; Nicole Endlich; Theodore E Warkentin; Thomas Renné
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476

Review 6.  Major coagulation disorders and parameters in COVID-19 patients.

Authors:  Azadeh Teimury; Mahshid Taheri Khameneh; Elahe Mahmoodi Khaledi
Journal:  Eur J Med Res       Date:  2022-02-15       Impact factor: 2.175

7.  A Case Report of Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination and Heparin Use During Hemodialysis.

Authors:  Young-Bin Son; Tae-Bum Kim; Hyeon-Jin Min; Jonghyun Lee; Jihyun Yang; Myung-Gyu Kim; Sang Kyung Jo; Won Yong Cho; Se Won Oh
Journal:  J Korean Med Sci       Date:  2022-03-14       Impact factor: 2.153

8.  Effects of SARS-CoV-2 mRNA vaccines on platelet polyphosphate levels and inflammation: A pilot study.

Authors:  Takashi Uematsu; Atsushi Sato; Hachidai Aizawa; Tetsuhiro Tsujino; Taisuke Watanabe; Kazushige Isobe; Hideo Kawabata; Yutaka Kitamura; Takaaki Tanaka; Tomoyuki Kawase
Journal:  Biomed Rep       Date:  2022-02-03

Review 9.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

Review 10.  Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Blood       Date:  2021-06-01       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.